Halozyme Therapeutics, Inc. (HALO) reported second-quarter 2024 adjusted earnings of 91 cents per share, which surpassed the Zacks Consensus Estimate of 78 cents. The company had recorded earnings of 74 cents per share in the year-ago period. Total revenues increased almost 5% year over year to $231.4 million in the second quarter. Revenues surpassed the Zacks Consensus Estimate of $211 million. The top line was driven by higher royalty payments from Roche (RHHBY) for Phesgo and higher sales of proprietary ...